Genmab — September 2019
-
Cross fingers for compelling data:-)
-
Kommer der data i morgen?
-
Mon det er Jan med klokken? It is our pleasure to ring the Nasdaq Opening Bell tomorrow. A livestream of the event will be available at 9:20 AM EDT on September 10 from the Nasdaq Facebook page: facebook.com/nasdaq
-
Afsked prospectively about the future threat of Ofatumumab Roche has suggested that it has experienced minimal pushback in Ocrevus adoption due to the dosing regimen; twice yerly IV administration closely track the typical rate of patient/psysician interactions the Company says. However feedback from the 60 neurologiske ( based in the US , France , Germany and UK ) we snap- polled suggest adoption of Ocrevus would have been even faster If administered in a different way with just under a third
-
Sikke en dejlig åbning vi er vidne til
-
Novartis confirmed last week that Ofatumumab has Met its primary and secondary endpoints in two phase III studies. Full data will be presented at ECTRIMS later this month and provide a much clearer indication how the efficacy of these two agents compares.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind